Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab

Modern Rheumatology

Volumn 16, Issue 6, 2006, Pages 381-388

  Kameda, Hideto ^a   Sekiguchi, Naoya ^a   Nagasawa, Hayato ^a   Amano, Koichi ^a   Takei, Hirofumi ^a   Suzuki, Katsuya ^a   Nishi, Eiko ^a   Ogawa, Hiroe ^a   Takeuchi, Tsutomu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Disease activity; Disease Activity Score with 28 joints (DAS28); Handy rheumatoid activity score with 38 joints (HRAS38); Infliximab; Modified Sharp score

Indexed keywords

CREACTIVE PROTEIN; FOLIC ACID; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR;

ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DOSE TIME EFFECT RELATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; JOINT FUNCTION; LINEAR REGRESSION ANALYSIS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RATING SCALE; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VISUAL ANALOG SCALE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DRUG THERAPY, COMBINATION; HUMANS; JOINTS; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845548758     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-006-0528-9     Document Type: Article

References (33)

1. WB van den Berg PLCM van Riel 2005 Uncoupling of inflammation and destruction in rheumatoid arthritis: Myth or reality? Arthritis Rheum 52 995-9 15818666 10.1002/art.20981
2. MA van Leeuwen DMFM van der Heijde MH van Rijswijk PM Houtman PLCM van Riel LBA van de Putte 1994 Inter-relationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants J Reumatol 21 425-9 1:STN:280:ByuB2srnsVQ%3D
3. T Takeuchi K Amano H Kameda 2006 Impact of TNF inhibitors on rheumatoid arthritis Inflammation Regeneration 26 148-59 10.2492/ inflammregen.26.148 1:CAS:528:DC%2BD28XmvFemtrk%3D
4. JS Smolen C Han M Bala RN Maini JR Kalden D van der Heijde 2005 Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement Arthritis Rheum 52 1020-30 15818697 10.1002/art.20982 1:CAS:528:DC%2BD2MXktFCksbk%3D
5. DT Felson JJ Anderson M Boers C Bombardier M Chernoff B Fried 1993 The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials Arthritis Rheum 36 729-40 8507213 1:STN:280:ByyB1c3os1c%3D
6. M Boers P Tugwell DT Felson PLCM van Riel JR Kirwan JP Edmonds 1994 A World Health Organization and Interstitial league of Association for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials J Rheumatol 21 suppl 41 86-9
7. DMFM van der Heijde MA van't Hof PLCM van Riel LAM Theunisse EW Lubberts MA van Leeuwen 1990 Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score Ann Rheum Dis 49 916-20 2256738 1:STN:280:By6D2snmtFQ%3D
8. DMFM van der Heijde MA van't Hof PLCM van Riel MA van Leeuwen MH van Rijswijk LBA van de Putte 1992 Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis Ann Rheum Dis 51 177-81 1550400 1:STN:280:By2C1MfhtVc%3D
9. MLL Prevoo MA van't Hof HH Kuper MA van Leeuwen LBA van de Putte PLCM van Riel 1995 Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44-8 7818570 1:STN:280:ByqC3MfjvFI%3D
10. American College of Rheumatology Committee on outcome measures in rheumatoid arthritis clinical trials 1994 Reduced joint count in rheumatoid arthritis clinical trials Arthritis Rheum 37 463-4
11. D van der Heijde 1999 How to read radiographs according to the Sharp/van der Heijde method J Rheumatol 26 743-5 10090194 1:STN:280:DyaK1M7ovVGrsg%3D%3D
12. JS Smolen FC Breedveld MH Schiff JR Kalden P Emery G Eberl PL van Riel P Tugwell 2003 A simplified activity index for rheumatoid arthritis for use in clinical practice Rheumatology 42 244-57 12595618 10.1093/ rheumatology/keg072 1:CAS:528:DC%2BD3sXit1yntLs%3D
13. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315-24 3358796 1:STN:280:BieC1M3nt1Q%3D
14. O Steinbrocker CH Traeger RC Batterman 1949 Therapeutic criteria in rheumatoid arthritis JAMA 140 659-62
15. MC Hochberg RW Chang I Dwosh S Lindsey T Pincus F Wolfe 1992 The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis Arthritis Rheum 35 498-502 1575785 1:STN:280:By2B2cjgsVA%3D
16. N Miyasaka T Takeuchi K Eguchi 2005 Proposed Japanese guidelines for the use of infliximab for rheumatoid arthritis Mod Rheumatol 15 4-8 17028815 10.1007/s10165-004-0357-7 1:CAS:528:DC%2BD2MXhsV2is7k%3D
17. DAS-score NL. Home of the DAS. http://www.das-score.nl/
18. DT Felson JJ Anderson M Boers C Bombardier D Furst C Goldsmith 1995 American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 727-35 7779114 1:STN:280:ByqB1MfgsFI%3D
19. AM van Gestel MLL Prevoo MA van't Hof MH van Rijswijk LBA van de Putte PLCM van Riel 1996 Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis Arthritis Rheum 39 34-40 8546736 1:STN:280:BymC3szisF0%3D
20. D van der Heijde L Simon J Smolen V Strand J Sharp M Boers 2002 How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion Arthritis Rheum 47 215-8 11954017 10.1002/art.10181
21. M Lassere M Boers D van der Heijde A Boonen J Edmonds A Saudan 1999 Smallest detectable difference in radiological progression J Rheumatol 26 731-9 10090192 1:STN:280:DyaK1M7ovVGkug%3D%3D
22. AM van Gestel CJ Haagsma PLCM van Riel 1998 Validation of rheumatoid arthritis improvement criteria that include simplified joint counts Arthritis Rheum 41 1845-50 9778226 10.1002/ 1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K 1:CAS:528:DyaK1cXmvFWmtrg%3D
23. HA Fuchs RH Brooks LF Callahan T Pincus 1989 A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis Arthritis Rheum 32 531-7 2719728 1:STN:280:BiaB2cnmtVw%3D
24. HA Fuchs T Pincus 1994 Reduced joint counts in controlled clinical trials in rheumatoid arthritis Arthritis Rheum 37 470-5 8147923 1:STN:280:ByuC1Mjnsl0%3D
25. IG Otternass 1994 The value of C-reactive protein measurement in rheumatoid arthritis Semin Arthritis Rheum 24 91-104 10.1016/ S0049-0172(05)80003-4
26. E Maini EW St Clair F Breedveld D Furst J Kalden M Weisman 1999 Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial Lancet 354 1932-9 10622295 10.1016/S0140-6736(99)05246-0 1:CAS:528:DC%2BD3cXit1Oquw%3D%3D
27. EW St. Clair DMFM van der Heijde JS Smolen RN Maini JM Bathon P Emery 2004 Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial Arthritis Rheum 50 3432-43 15529377 10.1002/art.20568 1:CAS:528:DC%2BD2cXhtVOqtrvJ
28. PE Lipsky DMFM van der Heijde EW St. Claire DE Furst FC Breedveld JR Kalden 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 1594-602 11096166 10.1056/NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D
29. H Kameda K Amano N Sekiguchi H Takei H Ogawa H Nagasawa 2004 Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: A better response in male patients Mod Rheumatol 14 442-6 10.1007/s10165-004-0340-3 1:CAS:528:DC%2BD2cXhtVGgtLnF
30. N Sekiguch H Kameda K Amano T Takeuchi 2006 Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis Mod Rheumatol 16 85-91 10.1007/s10165-005-0466-y
31. G Schett K Redlich S Hayer J Zwerina B Bolon C Dunstan 2003 Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice Arthritis Rheum 48 2042-51 12847699 10.1002/ art.11150 1:CAS:528:DC%2BD3sXmtFartbY%3D
32. E Lubberts L van den Bersselaar B Oppers-Walgreen P Schwarzenberger CJ Coenen-de Roo JK Kolls et Al 2003 IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κ B ligand/osteoprotegerin balance J Immunol 170 2655-62 12594294 1:CAS:528:DC%2BD3sXht12htLc%3D
33. AR Pettit H Ji D von Stechow R Muller SR Goldring Y Choi 2001 TRANCE/ RANKLE knockout mice are protected from bone erosion in a serum transfer model of arthritis Am J Pathol 159 1689-99 11696430 1:STN:280:DC%2BD3Mnltl2rsA%3D%3D